These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 24122913)

  • 1. Very large database of lipids: rationale and design.
    Martin SS; Blaha MJ; Toth PP; Joshi PH; McEvoy JW; Ahmed HM; Elshazly MB; Swiger KJ; Michos ED; Kwiterovich PO; Kulkarni KR; Chimera J; Cannon CP; Blumenthal RS; Jones SR
    Clin Cardiol; 2013 Nov; 36(11):641-8. PubMed ID: 24122913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dyslipidemia and changes in lipid profiles associated with rheumatoid arthritis and initiation of anti-tumor necrosis factor therapy.
    Curtis JR; John A; Baser O
    Arthritis Care Res (Hoboken); 2012 Sep; 64(9):1282-91. PubMed ID: 22504829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes.
    Kones R
    Vasc Health Risk Manag; 2013; 9():617-70. PubMed ID: 24174878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk.
    ; ;
    Atherosclerosis; 2019 Nov; 290():140-205. PubMed ID: 31591002
    [No Abstract]   [Full Text] [Related]  

  • 5. Results of retrospective chart review to determine improvement in lipid goal attainment in patients treated by high-volume prescribers of lipid-modifying drugs.
    Stacy TA; Egger A
    J Manag Care Pharm; 2006; 12(9):745-51. PubMed ID: 17249907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of the non-fasting lipid profile for lipid-lowering therapy in clinical practice - point of view.
    de Vries M; Klop B; Castro Cabezas M
    Atherosclerosis; 2014 Jun; 234(2):473-5. PubMed ID: 24814412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New dual peroxisome proliferator activated receptor agonist-Saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: integrated analysis of the real world evidence.
    Kaul U; Parmar D; Manjunath K; Shah M; Parmar K; Patil KP; Jaiswal A
    Cardiovasc Diabetol; 2019 Jun; 18(1):80. PubMed ID: 31208414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Lipid Measurements in Youth in Addition to Conventional Clinic-Based Risk Factors on Predicting Preclinical Atherosclerosis in Adulthood: International Childhood Cardiovascular Cohort Consortium.
    Koskinen J; Juonala M; Dwyer T; Venn A; Thomson R; Bazzano L; Berenson GS; Sabin MA; Burns TL; Viikari JSA; Woo JG; Urbina EM; Prineas R; Hutri-Kähönen N; Sinaiko A; Jacobs D; Steinberger J; Daniels S; Raitakari OT; Magnussen CG
    Circulation; 2018 Mar; 137(12):1246-1255. PubMed ID: 29170152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implications of coronary artery calcium testing on risk stratification for lipid-lowering therapy according to the 2016 European Society of Cardiology recommendations: The MESA study.
    Bittencourt MS; Blankstein R; Blaha MJ; Sandfort V; Agatston AS; Budoff MJ; Blumenthal RS; Krumholz HM; Nasir K
    Eur J Prev Cardiol; 2018 Nov; 25(17):1887-1898. PubMed ID: 30043629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes.
    Elam MB; Ginsberg HN; Lovato LC; Corson M; Largay J; Leiter LA; Lopez C; O'Connor PJ; Sweeney ME; Weiss D; Friedewald WT; Buse JB; Gerstein HC; Probstfield J; Grimm R; Ismail-Beigi F; Goff DC; Fleg JL; Rosenberg Y; Byington RP;
    JAMA Cardiol; 2017 Apr; 2(4):370-380. PubMed ID: 28030716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suboptimal lipid levels in clinical practice among Portuguese adults with dyslipidemia under lipid-lowering therapy: Data from the DISGEN-LIPID study.
    da Silva PM; Aguiar C; Morais J;
    Rev Port Cardiol (Engl Ed); 2019 Aug; 38(8):559-569. PubMed ID: 31706732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-Sensitivity C-Reactive Protein Discordance With Atherogenic Lipid Measures and Incidence of Atherosclerotic Cardiovascular Disease in Primary Prevention: The ARIC Study.
    Quispe R; Michos ED; Martin SS; Puri R; Toth PP; Al Suwaidi J; Banach M; Virani SS; Blumenthal RS; Jones SR; Elshazly MB
    J Am Heart Assoc; 2020 Feb; 9(3):e013600. PubMed ID: 32013698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypolipidemic drugs in elderly subjects: Indications and limits.
    Gazzola K; Vigna GB
    Nutr Metab Cardiovasc Dis; 2016 Dec; 26(12):1064-1070. PubMed ID: 27522161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe: EURIKA, a cross-sectional observational study.
    Halcox JP; Banegas JR; Roy C; Dallongeville J; De Backer G; Guallar E; Perk J; Hajage D; Henriksson KM; Borghi C
    BMC Cardiovasc Disord; 2017 Jun; 17(1):160. PubMed ID: 28623902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PCSK9 Inhibitor Use in the Real World: Data From the National Patient-Centered Research Network.
    Chamberlain AM; Gong Y; Shaw KM; Bian J; Song WL; Linton MF; Fonseca V; Price-Haywood E; Guhl E; King JB; Shah RU; Puro J; Shenkman E; Pawloski PA; Margolis KL; Hernandez AF; Cooper-DeHoff RM
    J Am Heart Assoc; 2019 May; 8(9):e011246. PubMed ID: 31020929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of and Factors Associated With the Prescription of Fibrates Among Patients Receiving Lipid-Lowering Drugs in Germany.
    Jacob L; Greiner RA; Luedde M; Kostev K
    J Cardiovasc Pharmacol; 2021 Dec; 78(6):885-890. PubMed ID: 34654787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidemiology of dyslipidemia and associated cardiovascular risk factors in northeast China: A cross-sectional study.
    Xing L; Jing L; Tian Y; Yan H; Zhang B; Sun Q; Dai D; Shi L; Liu D; Yang Z; Liu S
    Nutr Metab Cardiovasc Dis; 2020 Nov; 30(12):2262-2270. PubMed ID: 32988725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacology of Nutraceuticals with Lipid Lowering Properties.
    Poli A; Visioli F
    High Blood Press Cardiovasc Prev; 2019 Apr; 26(2):113-118. PubMed ID: 30877602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implications of cardiac risk and low-density lipoprotein cholesterol distributions in the United States for the diagnosis and treatment of dyslipidemia: data from National Health and Nutrition Examination Survey 1999 to 2002.
    Keevil JG; Cullen MW; Gangnon R; McBride PE; Stein JH
    Circulation; 2007 Mar; 115(11):1363-70. PubMed ID: 17353444
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.